Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
暂无分享,去创建一个
B. Neuschwander‐Tetri | N. Chalasani | J. Hoofnagle | M. V. Van Natta | D. Kleiner | K. Kowdley | Jeanne M Clark | A. Sanyal | J. Tonascia | A. McCullough | A. Diehl | N. Bass | E. Brunt | J. Lavine | A. Unalp | Patricia R. Robuck | J. Clark
[1] J. Hoofnagle,et al. The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis , 2007, Hepatology.
[2] G. Marchesini,et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. , 2001, Diabetes.
[3] N. Chalasani,et al. Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. , 2009, Contemporary clinical trials.
[4] J. Manson,et al. Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians' Health Study II randomized controlled trial. , 2009, JAMA.
[5] J. Clore,et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. , 2001, Gastroenterology.
[6] O. Cummings,et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.
[7] P. Hayashi,et al. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis , 2003, American Journal of Gastroenterology.
[8] Jonathan C. Cohen,et al. Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity , 2004, Hepatology.
[9] S. Sanderson,et al. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. , 2005, Journal of hepatology.
[10] M. Monami,et al. National Cholesterol Education Program and International Diabetes Federation definitions of metabolic syndrome in the prediction of diabetes. Results from the FIrenze‐Bagno A Ripoli study , 2008, Diabetes, obesity & metabolism.
[11] J. Ludwig,et al. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. , 1980, Mayo Clinic proceedings.
[12] B. Neuschwander‐Tetri,et al. Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): A histologic marker of advanced NAFLD—Clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network , 2009, Hepatology.
[13] J. Hardies,et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. , 2006, The New England journal of medicine.
[14] O. Cummings,et al. Relationship of steatosis grade and zonal location to histological features of steatohepatitis in adult patients with non-alcoholic fatty liver disease. , 2008, Journal of hepatology.
[15] C. McClain,et al. Mechanisms of non-alcoholic steatohepatitis. , 2004, Alcohol.
[16] J. Clore,et al. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. , 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[17] S. Caldwell,et al. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. , 2001 .
[18] W. Hall,et al. The AUDIT questionnaire: choosing a cut-off score. Alcohol Use Disorder Identification Test. , 1995, Addiction.
[19] G. FitzGerald,et al. Effects of vitamin E on lipid peroxidation in healthy persons. , 2001, JAMA.
[20] J. Goldblum,et al. Nonalcoholic fatty liver disease: assessment of variability in pathologic interpretations. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
[21] J. Manson,et al. Vitamin E in the Primary Prevention of Cardiovascular Disease and Cancer: The Women’s Health Study: A Randomized Controlled Trial , 2005, JAMA.
[22] Randall G. Lee. Nonalcoholic steatohepatitis: an expanded clinical entity: Bacon BR, Farakvash MJ, Janney CG, Neuschwander-Tetri BA. Gastroenterology 1994; 107: 1103–1109 , 1995 .
[23] P. Bejarano. Portal Chronic Inflammation in Nonalcoholic Fatty Liver Disease (NAFLD): A Histologic Marker of Advanced NAFLD—Clinicopathologic Correlations from the Nonalcoholic Steatohepatitis Clinical Research Network , 2010 .
[24] J. Hoofnagle,et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis , 2004, Hepatology.
[25] G. Gensini,et al. Pioglitazone and cardiovascular risk. A comprehensive meta‐analysis of randomized clinical trials , 2008, Diabetes, obesity & metabolism.
[26] S. Caldwell,et al. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis , 2001, American Journal of Gastroenterology.
[27] Chunhong Bai,et al. Long-term follow-up of patients with nonalcoholic fatty liver. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[28] Philippe Giral,et al. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. , 2008, Gastroenterology.
[29] Christian Gluud,et al. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. , 2007, JAMA.
[30] J. Lavine. Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. , 2000, The Journal of pediatrics.
[31] Roberto Pastor-Barriuso,et al. Meta-Analysis: High-Dosage Vitamin E Supplementation May Increase All-Cause Mortality , 2005, Annals of Internal Medicine.
[32] F. Violi,et al. Early decrease of oxidative stress by atorvastatin in hypercholesterolaemic patients: effect on circulating vitamin E. , 2007, European heart journal.
[33] P. Giral,et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. , 2005, Gastroenterology.
[34] R. Hanson,et al. The natural history of nonalcoholic steatohepatitis: A follow‐up study of forty‐two patients for up to 21 years , 1990, Hepatology.
[35] M. Holmqvist,et al. Long‐term follow‐up of patients with NAFLD and elevated liver enzymes , 2006, Hepatology.
[36] L. Willett. Vitamin E did not prevent cardiovascular disease and cancer in healthy women. , 2006, ACP journal club.
[37] P. Angulo. Corrections: Long-term mortality in nonalcoholic fatty liver disease: Is liver histology of any prognostic significance? , 2010 .
[38] B. Neuschwander‐Tetri,et al. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR‐γ ligand rosiglitazone , 2003, Hepatology.
[39] B. Neuschwander‐Tetri,et al. Nonalcoholic steatohepatitis: an expanded clinical entity. , 1994, Gastroenterology.
[40] Y. Israel,et al. Identification of alcohol abuse using laboratory tests and a history of trauma. , 1984, Annals of internal medicine.
[41] T. Hampton. Diabetes drugs tied to fractures in women. , 2007, JAMA.